The Diabetic Retinopathy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Diabetic Retinopathy Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Diabetic Retinopathy Market.
Some of the key takeaways from the Diabetic Retinopathy Pipeline Report:
- Companies across the globe are diligently working toward developing novel Diabetic Retinopathy treatment therapies with a considerable amount of success over the years.
- Diabetic Retinopathy companies working in the treatment market are Palatin Technologies, Avirmax Biopharma, Ocular Therapeutix, Inc., MingSight Pharmaceuticals, Inc, OcuTerra Therapeutics, Inc., RemeGen Co., Ltd, Kodiak Sciences Inc., and others, are developing therapies for the Diabetic Retinopathy treatment
- Emerging Diabetic Retinopathy therapies in the different phases of clinical trials are- PL8177, ABI-110, OTX-TKI, MS-553, OTT166, RC28-E injection, KSI-301, and others are expected to have a significant impact on the Diabetic Retinopathy market in the coming years.
- In May 2023, Oculic Holding AG unveiled favorable initial outcomes from Stage 1 of the Phase III DIAMOND trial concerning OCS-01 eye drops in diabetic macular edema (DME). The trial’s Stage 1 successfully confirmed the intended dosing regimen’s efficacy for OCS-01 in treating diabetic macular edema, achieving substantial statistical significance as per the company’s statement.
- In April 2023, Palatin Technologies announced the publication of a manuscript titled “Stimulating the Melanocortin System in Uveitis and Diabetes Preserves the Structure and Anti-Inflammatory Activity of the Retina” in The International Journal of Molecular Sciences. The manuscript, authored by Tat Fong Ng and Andrew W. Taylor from the Department of Ophthalmology at Boston University Chobanian and Avedisian School of Medicine in Massachusetts, summarizes findings on PL8331’s effects in experimental autoimmune uveoretinitis (EAU) and diabetic retinopathy (DR) in mouse models of retinal disease. The study received funding support from Palatin, the National Institute of Health (NIH), and the Massachusetts Lions Eye Research Foundation.
- In February 2023, Ocugen revealed the submission of an Investigational New Drug application (IND) to the US Food and Drug Administration (FDA) for the commencement of a Phase 1 clinical trial evaluating OCU200. This fusion protein, showcasing a unique mechanism of action (MOA), aims to address diabetic macular edema (DME). The accomplishment of this regulatory milestone fulfills Ocugen’s commitment to file the OCU200 IND within the initial quarter of 2023.
- In January 2023, Ocuphire Pharma disclosed the top-line findings of its ZETA-1 Phase II trial, assessing oral APX3330 for diabetic retinopathy (DR) treatment. The trial demonstrated promising safety and tolerability of oral APX3330, hinting at its potential as a non-invasive option for safeguarding vision in both eyes among patients with DR.
- In May 2022, EyePoint Pharmaceuticals disclosed the licensing agreement of EYP-1901 to Betta Pharmaceuticals for development and commercialization in China, Hong Kong, Macau, and Taiwan. While retaining all rights for EYP-1901 globally, EyePoint broadens its exclusive rights concerning the local delivery of vorolanib. This expansion encompasses the treatment of various ophthalmic diseases, encompassing diabetic macular edema (DME).
Diabetic Retinopathy Overview
One eye-related consequence of diabetes is diabetic retinopathy. Damage to the blood vessels in the retina, the light-sensitive tissue in the back of the eye, is the root cause of it. Diabetic retinopathy may initially only produce minor vision impairment or no symptoms at all. But blindness may result from it. Any person with type 1 or type 2 diabetes has the potential to acquire the illness.
Get a Free Sample PDF Report to know more about Diabetic Retinopathy Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/diabetic-retinopathy-pipeline-insight
Emerging Diabetic Retinopathy Drugs Under Different Phases of Clinical Development Include:
- PL8177: Palatin Technologies
- ABI-110: Avirmax Biopharma
- OTX-TKI: Ocular Therapeutix, Inc.
- MS-553: MingSight Pharmaceuticals, Inc
- OTT166: OcuTerra Therapeutics, Inc.
- RC28-E injection: RemeGen Co., Ltd.
- KSI-301: Kodiak Sciences Inc
Diabetic Retinopathy Route of Administration
Diabetic Retinopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
Diabetic Retinopathy Molecule Type
Diabetic Retinopathy Products have been categorized under various Molecule types, such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Diabetic Retinopathy Pipeline Therapeutics Assessment
- Diabetic Retinopathy Assessment by Product Type
- Diabetic Retinopathy By Stage and Product Type
- Diabetic Retinopathy Assessment by Route of Administration
- Diabetic Retinopathy By Stage and Route of Administration
- Diabetic Retinopathy Assessment by Molecule Type
- Diabetic Retinopathy by Stage and Molecule Type
DelveInsight’s Diabetic Retinopathy Report covers around 55+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Diabetic Retinopathy product details are provided in the report. Download the Diabetic Retinopathy pipeline report to learn more about the emerging Diabetic Retinopathy therapies
Some of the key companies in the Diabetic Retinopathy Therapeutics Market include:
Key companies developing therapies for Diabetic Retinopathy are – Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, Palatin Technologies, Valo Health, EyePoint Pharmaceuticals, Kubota Vision, MingSight Pharmaceuticals, Oxurion, Aerie Pharmaceuticals, AsclepiX Therapeutics, Ocugen, Ashvattha Therapeutics, Stealth BioTherapeutics, and others.
Diabetic Retinopathy Pipeline Analysis:
The Diabetic Retinopathy pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Diabetic Retinopathy with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetic Retinopathy Treatment.
- Diabetic Retinopathy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Diabetic Retinopathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetic Retinopathy market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Diabetic Retinopathy drugs and therapies
Diabetic Retinopathy Pipeline Market Drivers
- High healthcare Expenditure, increase in patient awareness about diabetes, presence of well-established healthcare infrastructure and favorable reimbursement framework are some of the important factors that are fueling the Diabetic Retinopathy Market.
Diabetic Retinopathy Pipeline Market Barriers
- However, poor access to care, out-of-pocket expenses, insufficient patient knowledge or awareness of Diabetic Retinopathy and other factors are creating obstacles in the Diabetic Retinopathy Market growth.
Scope of Diabetic Retinopathy Pipeline Drug Insight
- Coverage: Global
- Key Diabetic Retinopathy Companies: Palatin Technologies, Avirmax Biopharma, Ocular Therapeutix, Inc., MingSight Pharmaceuticals, Inc, OcuTerra Therapeutics, Inc., RemeGen Co., Ltd, Kodiak Sciences Inc., and others
- Key Diabetic Retinopathy Therapies: PL8177, ABI-110, OTX-TKI, MS-553, OTT166, RC28-E injection, KSI-301, and others
- Diabetic Retinopathy Therapeutic Assessment: Diabetic Retinopathy current marketed and Diabetic Retinopathy emerging therapies
- Diabetic Retinopathy Market Dynamics: Diabetic Retinopathy market drivers and Diabetic Retinopathy market barriers
Request for Sample PDF Report for Diabetic Retinopathy Pipeline Assessment and clinical trials
Table of Contents
1. Diabetic Retinopathy Report Introduction
2. Diabetic Retinopathy Executive Summary
3. Diabetic Retinopathy Overview
4. Diabetic Retinopathy- Analytical Perspective In-depth Commercial Assessment
5. Diabetic Retinopathy Pipeline Therapeutics
6. Diabetic Retinopathy Late Stage Products (Phase II/III)
7. Diabetic Retinopathy Mid Stage Products (Phase II)
8. Diabetic Retinopathy Early Stage Products (Phase I)
9. Diabetic Retinopathy Preclinical Stage Products
10. Diabetic Retinopathy Therapeutics Assessment
11. Diabetic Retinopathy Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Diabetic Retinopathy Key Companies
14. Diabetic Retinopathy Key Products
15. Diabetic Retinopathy Unmet Needs
16 . Diabetic Retinopathy Market Drivers and Barriers
17. Diabetic Retinopathy Future Perspectives and Conclusion
18. Diabetic Retinopathy Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/